Fouladi Joins Cancer Moonshot
Post Date: June 29, 2019 | Publish Date: May 18, 2016
“Her work is a prime example of the enormous potential impact of our new Proton Therapy Center and the genomics innovations occurring at Cincinnati Children’s.” — Margaret Hostetter, MD
Maryam Fouladi, MD, MSc, Medical Director, Brain Tumor Center, has been invited to participate in the National Cancer Moonshot initiative as a member of the Blue Ribbon Panel Working Group on Pediatric Cancer.
The Moonshot initiative, led by Vice President Joe Biden, aims to accelerate current cancer research efforts and break down barriers to progress, making more therapies available to more patients, while further improving early detection and cancer prevention efforts.
The National Cancer Institute (NCI) has assembled a blue ribbon panel and related working groups to provide expert advice on the vision, proposed scientific goals, and implementation of the National Cancer Moonshot. The panel will use input from the working groups to make recommendations to the NCI director on how to best advance the themes proposed for the Moonshot.
“This appointment recognizes Dr. Fouladi’s work as a national leader in brain cancer treatment and research,” says Margaret Hostetter, MD, Chair, Department of Pediatrics and Director, Cincinnati Children’s Research Foundation. “Her work is a prime example of the enormous potential impact of our new Proton Therapy Center and the genomics innovations occurring at Cincinnati Children’s.”
Fouladi moved to Cincinnati Children’s Hospital Medical Center in 2008 to become the medical director of the Neuro-Oncology Program. Fouladi is currently a full professor and the Marjory J. Johnson Endowed Chair in Brain Tumor Translational Research.
Fouladi was elected chair of the Pediatric Brain Tumor Consortium (PBTC) from 2012-2016. She has chaired multiple national and institutional Phase I, II, and III clinical trials of new agents for central nervous system (CNS) malignancies through the Children’s Oncology Group (COG), the Pediatric Brain Tumor Consortium (PBTC), and local studies. In 2016, Fouladi became the Chair of the CNS Committee of the COG.
Fouladi has extensive experience in the development and execution of trials, translational research and helping guide the agenda for pediatric neuro-oncology clinical trials nationally.